Sonnet BioTherapeutics Holdings (SONN) said Wednesday it has completed patient enrollment and begun dosing in the phase 1 trial of its investigational cancer therapy, SON-1010, for advanced solid tumors.
The company said it expects to report topline results in Q4.
The study, which involves 24 adult patients, is an open-label trial assessing the safety, tolerability, and pharmacokinetics of SON-1010 and is expected to help determine the maximum tolerated dose, Sonnet said.
Shares of the company were up 1.2% in recent Wednesday premarket activity.
Price: 0.9628, Change: +0.01, Percent Change: +1.24
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments